Loading
Life sciences · Journal article
Cell Death Discovery · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Metabolic plasticity is a hallmark of cancer cells. Simultaneous inhibition of oxidative phosphorylation and glycolysis is critical to limit tumor aggressiveness and therapy resistance. Recent repositioning of FDA-approved antifungal azoles in oncology highlights their translational potential. However, the antitumor activity and mechanistic basis of butoconazole remain unexplored, and no clinical studies have yet examined butoconazole or related azoles in liver cancer. Here, by integrating transcriptomic, biochemical, and functional assays, we identify butoconazole as a dual disruptor of mitochondrial functionality -via inhibition of Complex II and V- and of glycolytic metabolism in liver cancer, ultimately collapsing cellular bioenergetics. This metabolic exhaustion was accompanied by (i) altered autophagic flux and (ii) a marked suppression of proliferation, clonogenicity, and migration across multiple hepatocellular carcinoma cell lines, ultimately limiting tumor growth in vivo without systemic toxicity at the tested dose. Mechanistically, BN induces inflammatory, oxidative stress, and ATF4-dependent pathways, while downregulating canonical survival signaling, and nucleoporin genes linked with poor prognosis. Collectively, these findings position butoconazole as an efficient candidate for drug repositioning in hepatocellular carcinoma by targeting tumor metabolic flexibility and energy homeostasis.